We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Life Technologies to Collaborate with Boston Children's Hospital

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Life Technologies Corporation and Boston Children's Hospital has announced a research and development collaboration to develop an end-to-end genetic sequencing lab workflow based on Life Technologies' Ion Proton™ Sequencer.

The parties plan to collaborate and develop an optimized laboratory infrastructure and lab protocols for an advanced sequencing facility to be built at Boston Children's in compliance with CLIA and CAP certification standards.

The collaboration expects to benefit from Life Technologies' leading expertise in DNA sequencing technology and bioinformatics, and Boston Children's clinical research, genomics and informatics expertise.

Dr. David Margulies, director of The Gene Partnership Program at Boston Children's Hospital said: "This collaboration is an important first step toward providing informed, personalized care for patients whose conditions are difficult to treat. The development of an optimized laboratory infrastructure will support our mission of providing the highest quality, innovative and cost effective care to our patients."

Dr. Paul Billings, Chief Medical Officer at Life Technologies adds: "We are excited at the prospect of collaborating with the world-renowned experts in pediatric genetic disease at Boston Children's to develop and demonstrate best practices for using our proprietary Ion Torrent sequencing platform. Partnerships like these are essential to our Medical Sciences strategy as we seek to assist researchers in discovering improved diagnostics and treatments for genetic conditions."